Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for …
$8.45-7.50%
报价 2026-11-13
市值
$1.46B
EV
$1.81B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -30.2%
$2.30$12.10
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ABSIAbsci Corporation | $1.46B | -7.5% | +2.8% | -255.9% | – | – | – | |
| ERASErasca, Inc. | $5.5B | -0.8% | +837.5% | 0% | – | – | – | |
| MLTXMoonLake Immunotherapeutics | $1.06B | -2.9% | – | 0% | – | – | – | |
| VSTMVerastem, Inc. | $1.03B | -3.1% | +264.2% | 86.7% | – | – | – | |
| CRVSCorvus Pharmaceuticals, Inc. | $897.5M | +0.2% | +100.0% | 0% | – | – | – | |
| MGTXMeiraGTx Holdings plc | $881.7M | +4.4% | +1275.9% | 91.6% | – | – | – | |
| OLMAOlema Pharmaceuticals, Inc. | $662.3M | +0.5% | – | 0% | – | – | – | |
| RGNXREGENXBIO Inc. | $505.2M | -4.9% | -17.8% | 87.5% | – | – | – | |
| PRTAProthena Corporation plc | $419M | -0.9% | – | 95.3% | – | – | – | |
| 同行中位数 | – | – | +264.2% | 43.3% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。